SynthesisThe Journal of urology2015
A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer.
Synthesis in The Journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Perioperative and short-term outcomes of laparoscopic radical prostatectomy in elderly patients.World journal of surgical oncology · 2025Article
- Estimating patient health in prostate cancer treatment counseling.Prostate cancer and prostatic diseases · 2023Article
- Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer.Frontiers in oncology · 2022Article
- Article
- Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration.Urologic oncology · 2020Article
- Associations of multimorbidity and patient-reported experiences of care with conservative management among elderly patients with localized prostate cancer.Cancer medicine · 2020Article
- External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy.World journal of urology · 2019Article
- A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer.World journal of urology · 2019Article
- Decision Support Systems in Prostate Cancer Treatment: An Overview.BioMed research international · 2019Review
- Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.Future oncology (London, England) · 2018Article
- A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer.Targeted oncology · 2017Article
- The implications of ageing and life expectancy in prostate cancer treatment.Nature reviews. Urology · 2016Review
- Active surveillance for prostate cancer: current evidence and contemporary state of practice.Nature reviews. Urology · 2016Review
- Successful external validation of a model to predict other cause mortality in localized prostate cancer.BMC medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeWe aimed to develop a clinical decision support tool for clinicians counseling patients with localized prostate cancer. The tool would provide estimates of patient life expectancy based on age, comorbidities and tumor characteristics. We reviewed the literature to find suitable prediction models. MATERIALS AND
methodsWe searched the literature for prediction models for life expectancy. Models were evaluated in terms of whether they provided an estimate of risk, incorporated comorbidities, were clinically feasible and gave plausible estimates. Clinical feasibility was defined in terms of whether the model provided coefficients and could be used in the initial consultation for men across a wide age range without an undue burden of data gathering.
resultsModels in the literature were characterized by the use of life years rather than a risk of death, questionable approaches to comorbidities, implausible estimates, questionable recommendations and poor clinical feasibility. We found tools that involved applying an unvalidated approach to assessing comorbidities to a clearly erroneous life expectancy table, or requiring that a treatment decision be made before life expectancy could be calculated, or giving highly implausible estimates such as a substantial risk of prostate cancer specific mortality even for a highly comorbid 80-year-old with Gleason 6 disease.
conclusionsWe found gross deficiencies in current tools that predict risk of death from other causes. No existing model was suitable for implementation in our clinical decision support system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.